HDAC7 Protein is a protein involved in key cellular signaling pathways relevant to neurodegenerative diseases. This page provides comprehensive information about its structure, normal biological function, and role in disease pathogenesis.
HDAC7 Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions.
| HDAC7 Protein | |
|---|---|
| Protein Name | HDAC7 |
| Gene | [HDAC7](/genes/hdac7) |
| UniProt ID | Q8WUI4 |
| PDB Structure | 3C0Z, 5NTH, 5VNU |
| Molecular Weight | 103 kDa |
| Subcellular Localization | Primarily cytoplasm, translocates to nucleus upon signaling |
| Protein Family | Class IIa histone deacetylases |
HDAC7 contains an N-terminal catalytic domain and a C-terminal regulatory region. Like other class IIa HDACs, it has NLS and NES sequences and shuttles between cytoplasm and nucleus. HDAC7 binds to transcription factors including MEF2, FoxP3, and Nur77 in the cytoplasm, retaining them and repressing transcription. Upon signaling, HDAC7 translocates to the nucleus.
HDAC7 regulates gene expression through histone deacetylation. It is primarily cytoplasmic in resting cells, where it binds to and represses transcription factors. Upon cellular signaling, HDAC7 translocates to the nucleus. In neurons, HDAC7 regulates synaptic plasticity, neuronal differentiation, and stress responses. It also plays roles in vascular development and immune function.
HDAC7 is implicated in AD with altered expression and function in affected brains. HDAC7 regulates genes involved in neuronal survival and synaptic function. It also modulates APP processing. In cancer, HDAC7 is frequently overexpressed. HDAC7 inhibitors are being developed.
HDAC7 inhibitors are in development primarily for cancer. Like other class IIa HDACs, HDAC7 can be targeted with pan-HDAC inhibitors or more selective compounds. Challenges include achieving isoform specificity and brain penetration for neurological applications.